Vancouver, Canada, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the publication of a U.S. patent application expanding coverage of its non-hallucinogenic proprietary compound,...Read more
VANCOUVER, BC / ACCESS Newswire / October 30, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce that the Eurasian Patent Organization (EAPO) has issued a "Readiness to Grant" notification for the Company's comprehensive patent application for sublingual delivery of anticancer drugs for the treatment of...Read more
HOUSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral infections, today announced that the Australian Patent Office (IP Australia) has granted Patent No. 2024203598 titled, “PREPARATION OF PRELIPOSOMAL ANNAMYCIN LYOPHILIZATE,” with claims covering certain...Read more
DENVER, CO / ACCESS Newswire / October 28, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced that the method of use patent (U.S. Patent No. 7,538,116) for EXXUATM (gepirone) extended-release tablets ("EXXUA") has been extended through September 2,...Read more
Australian patent strengthens global patent portfolio SAN ANTONIO / Oct 28, 2025 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage diagnostics including CyPath® Lung, the Company’s noninvasive test for lung cancer, today announced that the Australian Patent Office (IP Australia) has accepted a patent application for the Company’s proprietary platform technology for...Read more
MELVILLE, N.Y., Oct. 27, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today announced a major intellectual property milestone: the Japanese Patent Office has issued a Notice of Allowance for the Company’s ThermoStem® platform. The newly allowed patent provides broad protection for...Read more
Expands global intellectual property coverage in markets with high breast cancer incidence New patent will provide IP protection of Breast Cancer Vaccine in China into 2040 SAN JOSE, Calif., Oct. 20, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the Chinese National Intellectual Property...Read more
Vancouver, Canada, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the publication of a U.S. patent application by the United States Patent and Trademark Office (USPTO) for its innovative...Read more
TEL AVIV, Israel, Oct. 20, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that its collaboration with Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind”) has led to the publication of a U.S. patent application by the United States...Read more
New patent marks Enveric’s 23rd issued U.S. patent for novel neuroplastogen molecules, increasing Enveric’s intellectual property footprint and supporting the potential for pipeline expansion CAMBRIDGE, Mass. / Oct 16, 2025 / Business Wire / Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological...Read more
U.S. award protects AI-built platform and adds to growing international patent portfolio SAN ANTONIO, Texas / Oct 16, 2025 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage cancer diagnostics including CyPath® Lung, the Company’s commercially available test for early-stage lung cancer, today announced it has received a notification of allowance from the United States...Read more
PALI-2108 is the first and only PDE4 inhibitor designed to target terminal ileum and colon for fibrostenotic Crohn’s disease (FSCD) and ulcerative colitis (UC) to address significant unmet medical needs Carlsbad, CA, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio,” or the “Company”), a clinical-stage biopharmaceutical company developing precision therapies for autoimmune,...Read more
Portfolio covers high-purity Z-endoxifen enteric formulations, performance characteristics, and manufacturing methods, part of Atossa's multi-jurisdiction IP strategy to support clinical and commercial plans SEATTLE, Oct. 13, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing new approaches in breast cancer treatment and prevention,...Read more
With over 120 issued and pending patent applications, Autonomix is building a comprehensive, global IP portfolio in nerve-sensing and modulation Newly issued patent strengthens the Company’s strategic position in a multi-billion-dollar market opportunity and unlocking potential across cardiovascular, renal, and other high-burden diseases THE WOODLANDS, TX, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:...Read more
BOSTON and LONDON, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced that it has filed two new provisional patent applications with the United States Patent and Trademark Office (USPTO). The first application includes claims protecting Akari’s novel immuno-oncology payload, PH1 (a novel Thailanstatin analog),...Read more
STATEN ISLAND, N.Y., Oct. 9, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, today announced that a new patent has been granted by the Australian Patent Office. This patent relates to DNA Polymerase IIIC...Read more
VANCOUVER, BC / ACCESS Newswire / October 9, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT) (OTCQB:BNXTF) (FSE:BXT), a bioscience innovator specializing in next-generation drug delivery technologies, today announced that it has completed a Track One priority patent filing with the U.S. Patent and Trademark Office (USPTO) for its proprietary sublingual thin-film cladribine formulation (BNT23001), designed for the...Read more
Nutriband files provisional patent application to enhance its AVERSA™ transdermal abuse deterrent technology being developed for patches containing opioids and stimulants with a potential for abuse. Nutriband’s AVERSA™ abuse-deterrent technology consists of a proprietary aversive agent coating that employs taste aversion to deter oral abuse and reduce accidental exposure. ORLANDO, Fla., Oct. 08, 2025 (GLOBE NEWSWIRE) --...Read more
SAN DIEGO, Oct. 08, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial-stage biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced the Opposition Division of the European Patent Office (the “EPO”) upheld the validity of all claims in EP 3678649, which is a patent validated in...Read more
New patents extend protection for Anaphylm™ into 2037 Anaphylm (dibutepinephrine) Sublingual Film, if approved by the FDA, will be the first and only oral medication for the rescue treatment of severe allergic reactions, including anaphylaxis WARREN, N.J., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful...Read more
This acceptance follow's Dermata's U.S. issued patent covering its Spongilla technology combination as a method to topically treat acne Dermata expects to launch a new once-weekly, Over-the-Counter (OTC) pharmaceutical acne kit, incorporating its Spongilla technology, in the middle of 2026 Over 3.3 million people are diagnosed with acne in Australia SAN DIEGO, CA, AL / ACCESS Newswire / October 2, 2025 / Dermata...Read more
Commercial Focus Remains on U.S. Market as it Continues to Explore Certain Global Markets that Accept FDA Cleared Devices Protecting its Innovative Technology Remains a Priority and Momentum Increasing as Global Jurisdictions Acknowledge the Uniqueness of the LIBERTY System HINGHAM, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer, manufacturer and distributer of the innovative LIBERTY®...Read more
Pioneering liquid biopsy platform for early lung cancer detection strengthens IP and accelerates commercial strategy in China and Japan diagnostic markets. Vancouver, British Columbia--(Newsfile Corp. - September 29, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy technologies for early cancer detection, is pleased to announce the formal grant of patents in...Read more
Patent covers esophagus produced using Humacyte’s proprietary bioengineered regenerative tissue platform, designed for implant in patients with damaged esophagus Patent provides coverage into 2041 for the composition of novel bioengineered esophagus DURHAM, N.C., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable,...Read more
HOUSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral infections, today announced that the Canadian Intellectual Property Office (CIPO) has issued a notice of allowance for Patent Application No. 3,142,510 titled, “PREPARATION OF PRELIPOSOMAL ANNAMYCIN...Read more
HOUSTON, TX, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Design Patent No. D1,092,758, entitled Transcranial Electro-Stimulation Device, providing 15 years of design protection for the Company’s...Read more
APOLLO BEACH, Fla., Sept. 25, 2025 (GLOBE NEWSWIRE) -- RetinalGenix Technologies Inc. (OTCQB:RTGN) (“RetinalGenix” or the “Company”), a pioneering developmental-stage ophthalmic monitoring and biopharmaceutical company focused on early detection and treatments for eye and systemic diseases, is proud to announce significant advancements in its patent portfolio, helping to position it at the forefront of home and remote health monitoring...Read more
MENIN inhibitors are a promising class of targeted oncology drugs in development for acute leukemias and certain solid tumors, but their use is often limited by severe dermatological side effects. HT-001 aims to address these toxicities, helping patients remain on therapy and realize the full benefit of treatment. Key Highlights U.S. Provisional Patents filed expanding HT-001's therapeutic reach. Indications...Read more
Patent portfolio secures innovation for the future of heart replacement TUCSON, Ariz., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first U.S. and Canadian commercially-approved total artificial heart, today announced the strengthening of its intellectual property portfolio with the recent grant of U.S....Read more
Patent covers advanced signal processing for middle ear sensors, further advancing the Company's position in leveraging the ear for fully implanted hearing devices White Bear Lake, Minnesota--(Newsfile Corp. - September 19, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced that it has received an Issue...Read more
EDEN PRAIRIE, Minn., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc., a fluid management company, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12,415,021 on September 16, 2025, based on Application No. 18/298,860. The patent relates to the use of one or more hemolysis sensors with extracorporeal blood filtration systems—such as ultrafiltration therapy and continuous renal replacement...Read more
The invention is designed to improve cryoprobe extraction, further reducing risk of tissue trauma, leading to lower costs and improved patient experience XSense™ System with Cryoprobes recently received regulatory approval in the U.S. and Israel CAESAREA, Israel, Sept. 18, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation...Read more
Grant of First Method of Use Patent Adds New Pillar to Grace’s Multi-layered Intellectual Property and Potential Market Exclusivity Protection Patent Coverage Extended to 2043 PRINCETON, N.J., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed...Read more
Intellectual property portfolio now includes 228 Patents and 153 Trademarks providing robust protection for the Company's product platforms in the rapidly growing multi-billion dollar veterinary diagnostics market ANN ARBOR, MI / ACCESS Newswire / September 18, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), an animal health company offering innovative point-of-care diagnostic and therapeutic device products for...Read more
BOSTON and LONDON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced that it has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) covering the Company’s antibody drug conjugate (ADC) platform using Akari’s spliceosome payload PH1 for treating cancer by...Read more
Provides Patent Protection in Europe Through at Least December 2040 Further IP Protection for TNX-103 (Oral Levosimendan) and Other Drug Formulations, and its Active Metabolites, in PH-HFpEF Also Provides Patent Protection for Wide Range of Levosimendan Doses, and its Use in Combination with Various Cardiovascular Drugs in PH-HFpEF CHAPEL HILL, N.C., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX)...Read more
Latest patent award strengthens competitive moat and reinforces leadership in medical navigation technology TYLER, Texas / Sep 15, 2025 / Business Wire / NanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or the “Company”), a medical technology company specializing in non-invasive therapeutic systems, today announced that the United States Patent and Trademark Office issued U.S. Patent No. 12,409,105 B2, titled “Insertion Device...Read more
A Phase 2 study for NT219 in combination with immunotherapy is being conducted in collaboration with the University of Colorado REHOVOT, Israel, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced that the Examining Division of the...Read more
SARASOTA, FL, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced that the Japan Patent Office has granted patent number 7683882 to Silo’s research and licensing partner Columbia University for the invention titled “Prophylactic efficacy of serotonin 4 receptor agonists against stress,”...Read more
Additional patent granted from the Japanese patent office now results in 20 granted patents and allowed applications covering the compound and its underlying technology SOUTH SAN FRANSCISCO, Calif., Sept. 09, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative cellular immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that...Read more
Patents strengthen Envoy Medical's innovation pipeline and protect next-generation cochlear implant solutions for individuals living with hearing loss. White Bear Lake, Minnesota--(Newsfile Corp. - September 9, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced the issuance of four new global patents. These patents...Read more
Nes-Ziona, Israel, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the issuance of an Israeli patent, numbered 290470, titled, “THERAPEUTIC APOPTOTIC CELLS FOR TREATMENT OF OSTEOARTHRITIS”. The patent will provide Enlivex with added intellectual property protection in Israel through at least 2040 with claims...Read more
Fifth U.S. Patent Directed to Use of Vidofludimus Calcium in Multiple Sclerosis Comprehensive Intellectual Property Strategy Secures Protection Into 2041 in the U.S., Unless Extended Further NEW YORK, Sept. 9, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases,...Read more
TORONTO and HAIFA, Israel, Sept. 08, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a pioneering biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce that the United States Patent and Trademark Office has issued a Notice of Allowance for a patent covering the Company’s proprietary process for producing exosomes, natural...Read more
Strengthens the Company’s intellectual property portfolio for lead in vivo program PBGENE-HBV with U.S. patent protection into 2042 Phase 1 ELIMINATE-B trial progressing through clinical investigation with dosing of Cohort 3 initiated in Third Quarter of 2025 DURHAM, N.C. / Sep 08, 2025 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to...Read more
Patent strengthens company’s leadership in feeding tube placement and opens path to broader vascular navigation market TYLER, Texas / Sep 04, 2025 / Business Wire / NanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or the “Company”), a medical technology company specializing in non-invasive therapeutic systems, today announced that the United States Patent and Trademark Office issued U.S. Patent No. 12,402,953 B2, titled “Insertion...Read more
Patent grant broadens IP protection in Asia and complements prior patents in Europe, the United States and India Hong Kong represents a meaningful diabetes market and a critical gateway into Mainland China—including the Greater Bay Area—supporting future clinical collaboration, partnering and commercialization paths for IsletRx ZURICH, Sept. 4, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP) ("NLS" or the "Company")...Read more
SAN DIEGO, Sept. 3, 2025 /PRNewswire/ -- Aethlon Medical, Inc. ("Aethlon" or the "Company") (Nasdaq: AEMD) announced that U.S. Patent No. 12,409,260 (the "260 Patent") directed to treatment of Long COVID will issue on September 9, 2025, and Unitary European Patent 4136453 (the "453 Patent") directed to the treatment of COVID-19-associated coagulopathy ("CAC") issued July 9, 2025. The 260 Patent is intended to protect the use of the...Read more
Kennewick, WA, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) Vivos Inc filed a provisional patent No.: 63/873,014 - STERILE THERMOGELS Vivos Inc. is pleased to announce the successful validation of a new electron beam (E-Beam) sterilization process for our hydrogel, marking a culmination of nearly a year of testing and validation of a process that was only viable because of the unique characteristics of our hydrogel. The...Read more
SARASOTA, FL, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced that IP Australia (the Australian Patent Office) has granted patent number 2020271839 to Silo’s research and licensing partner Columbia University for the invention titled “Prophylactic efficacy of serotonin 4 receptor agonists...Read more
U.S. patent protection covers computer-aided diagnosis (“CADx”) with breast CT Izotropic holds the exclusive rights to this patent and breast CT technology under global license agreement CADx upgrade to be integrated into IzoView Breast CT post-initial market launch, feature may be offered as an upgrade incentive to early adopters VANCOUVER, British Columbia, and SACRAMENTO, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE)...Read more
POTOMAC, MD / ACCESS Newswire / August 28, 2025 / IGC Pharma, Inc. (NYSE American:IGC) today announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its patent application US 17/613,909. The patent application, IGC510, is for a proprietary method for treating individuals suffering from stammering, stuttering, or Tourette's syndrome with THC and/or CBD. A notice of allowance ("NOA")...Read more
Plans to seek FDA submission and approval for first-in-human trials in type 1 diabetes and stiff person syndrome targeted for early 2026 MOUNTAIN VIEW, Calif. / Aug 25, 2025 / Business Wire / Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt”, or the “Company”), a social innovation platform accelerating promising health innovations, today announced an update on its wholly owned subsidiary Adimune, Inc. (“Adimune”), which is pioneering a DNA-based...Read more
Recorlev now holds four Orange Book-listed patents to 2040 CHICAGO / Aug 25, 2025 / Business Wire / Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced the U.S Patent and Trademark Office has issued patent number 12,377,096 to the Company for Recorlev®...Read more
RA'ANANA, Israel, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," “Inspira Technologies,” or the "Company"), a pioneer in innovative life-support and diagnostic technologies, has received U.S. Patent approval for low flow rates extracorporeal oxygenation system and methods of use. This patent represents the core technology of the ART500 device, a key asset in the Company’s strategy to...Read more
SOLANA BEACH, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that U.S. Patent No. 12,377,064 covering the use of GIMOTI® (metoclopramide) nasal spray in patients with moderate to severe symptoms of gastroparesis, has been listed in the...Read more
Notice of Allowance marks first Chinese patent to be issued on Anixa Breast Cancer Vaccine Expands global intellectual property coverage in markets with high breast cancer incidence New patent will provide IP protection of Breast Cancer Vaccine in China into at least the 2040s SAN JOSE, Calif., Aug. 20, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on...Read more
Global patent estate encompasses 80 issued patents and 40 pending patent applications Strengthens strategic position in a multi-billion-dollar market opportunity across cardiovascular, renal, and other high-burden diseases THE WOODLANDS, TX, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments,...Read more
With the Newly Granted IP, the Company’s IP Portfolio for the LIBERTY® System now includes 12 patents granted globally and 57 patent applications pending. The Company Continues to Scale Commercial Readiness Plans for the LIBERTY® System as it Awaits FDA Decision. HINGHAM, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, today announced...Read more
Patents issued in the U.S., Australia, and Hong Kong advance Envoy Medical's innovation pipeline and protect next-generation cochlear implant solutions for individuals living with hearing loss. White Bear Lake, Minnesota--(Newsfile Corp. - August 20, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced the issuance...Read more
VANCOUVER, BC / ACCESS Newswire / August 20, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT) (OTC PINK:BNXTF) (FSE:BXT), a bioscience company specializing in innovative drug delivery technologies, is pleased to announce two key milestones in the expansion and protection of its proprietary drug delivery platform targeting neurological autoimmune disorders. The Company has formally initiated the prioritized examination...Read more
Calgary, Alberta--(Newsfile Corp. - August 18, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively "Marvel" or the "Company"), a drug discovery company developing novel therapeutics for autism spectrum disorder and related conditions, today announced that the China National Intellectual Property Administration (CNIPA) has granted patent number...Read more
Strengthens Intellectual Property Estate for REQORSA Oncology Program with Immune Checkpoint Inhibitors AUSTIN, Texas, Aug. 18, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent to...Read more
Ensures Intellectual Property Protection Until 2040 LOS ALTOS, Calif., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced the issuance of U.S. Patent 12,377,082 by the U.S. Patent and Trademark Office for UNI-494 to treat Chronic Kidney Disease (CKD). This patent...Read more
BURLINGTON, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, announced today that it has received five Notices of Allowance from the United States Patent and Trademark Office (USPTO) for patent applications covering their latest furosemide formulation, SCP-111. The SCP-111...Read more
RED BANK, NEW JERSEY / ACCESS Newswire / August 13, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company dedicated to developing innovative therapeutic candidates for inflammation, immunology, and critical unmet medical needs, today announced a significant expansion of its intellectual property portfolio for TH-104, its novel transmucosal film. The new patents, recently granted and...Read more
Newly issued patent extends protection of proprietary solid tumor CAR-T platform to 2045 SAN JOSE, Calif., Aug. 12, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent Number 12,384,826 covering its chimeric antigen receptor-T...Read more
U.S. Patent No. 12379378-B2 protects biomarker-driven systems and methods to assess progression risk in Barrett’s esophagus and esophageal adenocarcinoma; issuance follows the successful BE-Smart™ test validation (>95% technical success) and, together with BE-Smart’s demonstrated compatibility with both brush and forceps biopsies, supports earlier detection. UNIONDALE, NY, Aug. 12, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc....Read more
Extends Patent Protection Through December 2041 ART27.13 is Currently under Evaluation in a Phase 2 Study for the Treatment of Cancer-Related Anorexia SOLANA BEACH, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological...Read more
HIGH POINT, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent...Read more
Annovis achieves comprehensive intellectual property (IP) protection now covering both the original semi-crystalline and new crystalline forms of buntanetap. Both forms are covered by a total of 13 patent families. All patents are filed internationally, securing global coverage of buntanetap. MALVERN, Pa., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug...Read more
Vancouver, Canada, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the publication of an international patent application under the Patent Cooperation Treaty (PCT) as part of its ongoing...Read more
Extends market exclusivity for GIMOTI® to November 2038, nearly two additional years beyond original 2036 projection SOLANA BEACH, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced the official issuance of a new U.S. patent related to...Read more
VANCOUVER, BC / ACCESS Newswire / August 5, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE: BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in innovative drug delivery technologies, is pleased to announce significant progress in its global patent portfolio. The Company has received formal communications from both the European Patent Office (EPO) and the Eurasian Patent Organization (EAPO), confirming that...Read more
CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal has upheld the validity of Moderna's EP'949 patent. This decision affirms the High Court's initial ruling from July 2024 that the EP'949 patent is valid and infringed by Pfizer/BioNTech's COVID-19 vaccine, Comirnaty®, which was subsequently appealed by Pfizer/BioNTech. With this ruling, the UK becomes the first...Read more
PALI-2108 is the first and only PDE4 inhibitor designed to target terminal ileum and colon for fibrostenotic Crohn’s disease (FSCD) and ulcerative colitis (UC), to address significant unmet medical needs Inflammatory Bowel Disease is a large and growing market opportunity in China, with forecasts approaching $1B in total revenues by 2030 Carlsbad, CA, July 31, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,”...Read more
Granted patents provide broad composition, formulation, and method of use protection across key global markets including use of MDNA11 in combination with checkpoint inhibitors and a novel formulation of bizaxofusp TORONTO and HOUSTON, July 31, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company developing novel Superkines for...Read more
New patent enhances market position in Europe HOUSTON, July 30, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced it has received a Notice of Intent to Grant for the European patent application titled, “PREPARATION OF PRELIPOSOMAL ANNAMYCIN...Read more
NEW YORK and SANTA BARBARA, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) (the “Company”) today announces that on July 18, 2025, the Japanese Patent Office granted Patent JP 7714571B, a patent which runs until March 31, 2041. This patent underpins one of the Company’s key pipeline assets, a modified stilbenoid, and importantly provides the Company with exclusivity to particular compounds per se,...Read more
Vancouver, Canada, July 30, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the filing of a new international patent application under the Patent Cooperation Treaty (PCT). The application covers its...Read more
Patent Strengthens International Protection for First-of-Its-Kind Immunopreventive Platform Expands Global IP Coverage in Markets with High Incidence of Breast Cancer SAN JOSE, Calif., July 30, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the Canadian Intellectual Property Office (CIPO) has...Read more
PHILADELPHIA and VANCOUVER, British Columbia, July 30, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announces that it has been granted New Zealand Patent No. 785587 titled “WHOLE-CELL CANCER VACCINES AND METHODS FOR SELECTION THEREOF”. The patent covers...Read more
TILsRx platform designed to overcome immune suppression and T cell exhaustion to activate tumor-infiltrating lymphocytes (TILs) Multivalent technology enables simultaneous engagement of multiple cancer-associated and immune pathway targets A preferred tolerability profile is expected due to selective cancer cell targeting within the tumor microenvironment (TME) TILsRx platform early agents include antibodies to B7-H3, an immune...Read more
Strategic IP expansion protects federated learning technology driving pharma partnerships, biosecurity initiatives, and precision medicine growth LOS ANGELES, CALIFORNIA / ACCESS Newswire / July 28, 2025 / Renovaro (NASDAQ:RENB), a precision-medicine technology company, today announced multiple U.S. patent allowances that significantly strengthen its competitive position in biomedical artificial intelligence. The new patents,...Read more
HOUSTON, July 28, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the filing of a patent application with the United States Patent and Trademark Office covering methods of generating...Read more
Patent Expands Immunogenic Coverage of α-Lactalbumin-Based Vaccine Platform Technology Addresses Substantial Unmet Need in Preventive Oncology with Multi-Billion Dollar Market Potential SAN JOSE, Calif., July 24, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the United States Patent and...Read more
Patent Strengthens Intellectual Property Portfolio Surrounding Neural Probe Technologies EDEN PRAIRIE, Minn., July 23, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, has received a notice of allowance for a key patent from the U.S....Read more
Patent-protected methylone-inspired analogs support pipeline expansion into PTSD CAMBRIDGE, Mass. / Jul 23, 2025 / Business Wire / Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced a second Notice of Allowance from the United States Patent and Trademark Office (USPTO) for...Read more
New patent protects market expansion to the north where lung cancer is leading cause of cancer deaths SAN ANTONIO / Jul 22, 2025 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage cancer diagnostics including CyPath® Lung, the Company’s commercially available test for early-stage lung cancer, today announced its patent related to a method to detect lung disease through...Read more
Encinitas, California--(Newsfile Corp. - July 22, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced it has received a patent (US Patent No. 12,364,680) covering KIO-104 for the treatment of a wide range of ocular diseases. This includes, but is not limited to, the following conditions: ocular inflammation, uveitis, age-related macular degeneration, and complications from refractive surgery. Additionally, the patent covers...Read more
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE